Early Cellular Responses to Tumor Treating Fields in Glioblastoma

Clicks: 11
ID: 328091
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #128 of 144 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 144 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Tumor Treating Fields (TTFields) are a clinically validated therapy that has contributed to improved survival outcomes in glioblastoma patients. A deeper understanding of the underlying cellular mechanisms of TTFields could further advance therapeutic strategies. Here we explore the early impact of TTFields on cell cycle dynamics to inform potential synergistic adjunctive approaches. Methods We analyzed TTFields-induced alterations in cell cycle distribution in synchronized glioblastoma cells via flow cytometry, and in asynchronous cells through live-cell imaging of PIP-FUCCI-transduced cells. Replication stress was assessed via the DNA fiber assay. To investigate potential therapeutic synergies, we evaluated the effects of TTFields together with cell cycle–targeting agents (Chk1, ATR, and Wee1 inhibitors) on clonogenic survival. Finally, we validated the impact of TTFields in tumor-bearing mice using the inovivo™ system. Results TTFields induced a pronounced G2-phase arrest in synchronized glioblastoma cells. Importantly, live-cell imaging revealed that cell cycle progression delays occurred very early after TTFields exposure in S, G2 and G1 cell cycle phases. TTFields triggered replication stress, and pharmacological inhibition of Wee1, ATR, or Chk1 significantly increased the sensitivity of glioblastoma cells to TTFields. Notably, these early alterations in cell-cycle progression and replication dynamics occurred in the absence of overt DNA damage following TTFields exposure in both in vitro and in vivo glioblastoma models. Conclusions TTFields induce early alterations in cell-cycle progression and replication dynamics without evidence of overt DNA damage at the investigated time points in glioblastoma models. These findings identify cell-cycle checkpoint pathways as a potential therapeutic vulnerability and support further evaluation of cell-cycle–targeting agents concurrently with TTFields.
Reference Key
openalex_W7212151955 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Claire O'Leary, Gabriella Forte, Paul L G Slangen, Caroline van Heijningen, Marjolijn Mertz, Bram van den Broek, Lenno Krenning, Kees Jalink, Basma El Bakary, Federico Roncaroli, Mark C. de Gooijer, Olaf van Tellingen, Gerben R. Borst
Are you one of these authors? Claim your profile
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag244
URL
https://doi.org/10.1093/noajnl/vdag244
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.